Table 1 Comparison between AS and nrAxSpA
nrAxSpA (N = 63) | AS (N = 96) | P | |
|---|---|---|---|
Age (years) | 21.0 [20.0;21.0] | 21.0 [20.0;22.0] | 0.739 |
Symptom duration (years) | 1.0 [0.3; 2.0] | 2.0 [0.5; 3.0] | 0.186 |
Peripheral arthritis (%) | 36 (57.1%) | 41 (42.7%) | 0.105 |
Enthesitis (%) | 25 (39.7%) | 16 (16.7%) | 0.002 |
Uveitis (%) | 7 (11.1%) | 14 (14.6%) | 0.694 |
Dactylitis (%) | 3 (4.8%) | 1 (1.0%) | 0.343 |
Psoriasis (%) | 1 (1.6%) | 3 (3.1%) | 0.930 |
Inflammatory bowel disease (%) | 0 | 0 | 1.000 |
CRP elevation (%) | 23 (37.1%) | 61 (63.5%) | 0.002 |
Alternating buttock pain (%) | 26 (41.3%) | 66 (68.8%) | 0.001 |
Good response to NSAID (%) | 42 (66.7%) | 61 (63.5%) | 0.815 |
Family history of SpA (%) | 9 (14.3%) | 13 (13.5%) | 1.000 |
HLA-B27 positivity (%) | 49 (77.8%) | 85 (88.5%) | 0.109 |
ESR (mm/hr) | 2.0 [2.0;11.0] | 10.5 [3.0;23.0] | < 0.0001 |
CRP (mg/dL) | 0.1 [0.0; 0.8] | 0.6 [0.2; 1.6] | < 0.0001 |
Right sacroiliitis grade | 1.0 [0.0; 1.0] | 3.0 [2.0; 3.0] | < 0.0001 |
Left sacroiliitis grade | 1.0 [0.0; 1.5] | 3.0 [2.0; 3.0] | < 0.0001 |
mSASSS | 0.0 [0.0; 0.0] | 0.0 [0.0; 0.0] | 0.088 |
Presence of syndesmophyte (%) | 0 (0.0%) | 6 (9.2%) | 0.110 |
SPARCC score of BMO (0–48) | 4.0 [0.0; 8.5] | 12.0 [7.0;19.0] | < 0.0001 |
SPARCC score of intense oedema (0–12) | 0.0 [0.0; 0.0] | 0.0 [0.0; 0.5] | 0.015 |
SPARCC score of deep oedema (0–12) | 0.0 [0.0; 0.0] | 2.0 [0.0; 5.5] | < 0.0001 |
Total inflammatory SPARCC score of SIJ (0–72) | 5.0 [0.0; 9.5] | 14.0 [7.0;25.5] | < 0.0001 |